Ischaemic stroke – prevention is better than cure

1 Rothwell PM Coull AJ Silver LE Population-based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study). Lancet 2005; 366:1773–83. doi:10.1016/S0140-6736(05)67702-1

2 Geddes JM Fear J Tennant A Prevalence of self-reported stroke in a population in northern England. J Epidemiol Commun Health 1996; 50:140–3. doi:10.1136/jech.50.2.140

3 O’Mahony PG Thomson RG Dobson R The prevalence of stroke and associated disability. J Public Health Med 1999; 21:166–71. doi:10.1093/pubmed/21.2.166

4 Bamford J Sandercock P Dennis M A prospective study of acute cerebrovascular disease in the community: the Oxfordshire Community Stroke Project 1981–1986. 2. Incidence, case fatality rates and overall outcome at one year of cerebral infarction, primary intracerebral and subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry 1990; 53:16–22.

5 Anderson CS Jamrozik KD Broadhurst RJ Predicting survival for one year among different subtypes of strokes: results from the Perth Community Stroke Study. Stroke 1994; 25:1935–44.

6 Wardlaw JM Murray V Berge E Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev 2009; 4: CD000213. doi: 10.1002/14651858.CD000213.pub2

7 Sandercock PAG Counsell C Gubitz GJ Antiplatelet therapy for acute ischaemic stroke. Cochrane Database Syst Rev 2008; 3: CD000029. doi: 10.1002/14651858.CD000029.pub2

8Stroke Unit Trialists’ Collaboration. Organised inpatient (stroke unit) care for stroke. Cochrane Database Syst Rev 2007; 4: CD000197. doi: 10.1002/14651858.CD000197.pub2

9 Hofmeijer J Kappelle LJ Algra A Surgical decompression for space-occupying cerebral infarction (the Hemicraniectomy After Middle Cerebral Artery infarction with Life-threatening Edema Trial [HAMLET]): a multicentre, open, randomised trial. Lancet Neurol 2009; 8:326–33. doi:10.1016/S1474-4422(09)70047-X

10Royal College of Physicians of London (RCPL). National sentinel stroke audit phase II (clinical audit) 2008. London: RCPL; 2009. Available from: http://www.rcplondon.ac.uk/clinical-standards/ceeu/Current-work/stroke/Documents/stroke-audit-report-2008.pdf

11 Huttner HB Schwab S. Malignant middle cerebral artery infarction: clinical characteristics, treatment strategies, and future perspectives. Lancet Neurol 2009; 8:949–58. doi:10.1016/S1474-4422(09)70224-8

12 Sudlow C Warlow C. Getting the priorities right for stroke care. BMJ 2009; 338:1419–22. doi:10.1136/bmj.b2083

13 Feigin VL Lawes CM Bennett DA Worldwide stroke incidence and early case fatality reported in 56 population-based studies: a systematic review. Lancet Neurol 2009; 8:355–69. doi:10.1016/S1474-4422(09)70025-0

14 Chandratheva A Mehta Z Geraghty OC Population-based study of risk and predictors of stroke in the first few hours after a TIA. Neurology 2009; 72:1941–7. doi:10.1212/WNL.0b013e3181a826ad

15 Pendlebury ST Risk of recurrent stroke Rothwell PM. attack other vascular events and dementia after transient ischaemic and stroke. Cerebrovasc Dis 2009; 27 (Suppl 3):1–11. doi:10.1159/000209260

16 Rothwell PM Eliasziw M Gutnikov SA Pooled analysis of individual patient data from randomised controlled trials of endarterectomy for symptomatic carotid stenosis. Lancet 2003; 361:107–16. doi:10.1016/S0140-6736(03)12228-3

17 Rothwell PM. Poor outcomes after endovascular treatment of symptomatic carotid stenosis: time for a moratorium. Lancet Neurol 2009; 8:871–3. doi:10.1016/S1474-4422(09)70230-3

18 Algra A Van Gijn J. Cumulative meta-analysis of aspirin efficacy after cerebral ischaemia of arterial origin. J Neurol Neurosurg Psychiatry 1999; 66:255. doi:10.1136/jnnp.66.2.255

19 Halkes PH Gray LJ Bath PM Dipyridamole plus aspirin versus aspirin alone in secondary prevention after TIA or stroke: a metaanalysis by risk. J Neurol Neurosurg Psychiatry 2008; 79:1218–23. doi:10.1136/jnnp.2008.143875

20 Halkes PHA , Van Gijn, Kappelle LJ Risk indicators for development of headache during dipyridamole treatment after cerebral ischaemia of arterial origin. J Neurol Neurosurg Psychiatry 2009; 80:437–9. doi:10.1136/jnnp.2008.147918

21 Sacco RL Diener H-C Yusuf S Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. The Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial. N Engl J Med 2008; 359:1238–51. doi:10.1056/NEJMoa0805002

22EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993; 342:1255–62.

23 Saxena R Koudstaal PJ. Anticoagulants for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischaemic attack. Cochrane Database Syst Rev 2003; 3: CD000185. doi: 10.1002/14651858.CD000185.pub2

24 Hart RG Pearce LA Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146:857–67.

25 Law MR Morris JK Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338:b1665.

26 Messerli FH Williams B Ritz E. Essential hypertension. Lancet 2007; 370:591–603. doi:10.1016/S0140-6736(07)61299-9

27 Amarenco P Labreuche J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol 2009; 8:453–63. doi:10.1016/S1474- 4422(09)70058-4

28 Ray KK Seshasai SRK Wijesuriya S Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009; 373:1765–72. doi:10.1016/S0140-6736(09)60697-8

29 Röther J Alberts MJ Touzé E Risk factor profile and management of cerebrovascular patients in the REACH Registry. Cerebrovasc Dis 2008; 25:366–74. doi:10.1159/000120687

30 Shinton R Beevers G. Meta-analysis of relation between cigarette smoking and stroke. BMJ 1989; 298:789–94. doi:10.1136/bmj.298.6676.789

31 Rose G. Strategy of prevention: lessons from cardiovascular disease. BMJ 1981; 282:1847–51. doi:10.1136/bmj.282.6279.1847

32 Connolly SJ MD Ezekowitz ,Yusuf S Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361:1139–51. doi:10.1056/NEJMoa0905561

33Antithrombotic Trialists’ Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative metaanalysis of individual participant data from randomised trials. Lancet 2009; 373:1849–60. doi:10.1016/S0140-6736(09)60503-1

34 Abbott A. Medical (nonsurgical) intervention alone is now best for prevention of stroke associated with asymptomatic severe carotid stenosis. Results of a systematic review and analysis. Stroke 2009; 40:e573–83. doi:10.1161/STROKEAHA.109.556068

35 Marquardt L Geraghty OC Mehta Z Low risk of ipsilateral stroke in patients with asymptomatic carotid stenosis on best medical treatment. A prospective, population-based study. Stroke 2010; 41:e11–7.

36 Standing P Deakin H Norman P Hypertension – its detection, prevalence, control and treatment in a quality driven British general practice. Br J Cardiol 2005; 12:471–6.

37 Jamrozik K Broadhurst RJ Anderson CS The role of lifestyle factors in the etiology of stroke. A population-based case-control study in Perth, Western Australia. Stroke 1994; 25:51–9.

38 Lawes CM S Vander Hoorn Rodgers A International Society of H ypertension. Global burden of blood-pressure-related disease, 2001. Lancet 2008; 371:1513–8. doi:10.1016/S0140-6736(08)60655-8

39 Tolonen H Keil U Ferrario M Prevalence, awareness and treatment of hypercholesterolaemia in 32 populations: results from the WHO MONICA Project. Int J Epidemiol 2005; 34:181–92. doi:10.1093/ije/dyi056

40 Bronner LL Kanter DS Manson JE. Primary prevention of stroke. N Engl J Med 1995; 333:1392–400. doi:10.1056/NEJM199511233332106

41 Brugts JJ Yetgin T Hoeks SE The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ 2009; 338:b2376. doi:10.1136/bmj.b2376

42 Feinberg WM Blackshear JL Laupacis A Prevalence, age distribution, and gender of patients with atrial fibrillation: analysis and implications. Arch Intern Med 1995; 155:469–73. doi:10.1001/archinte.155.5.469

43 Wolf PA Abbott RD Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22:983–8.

44 Wolf PA Mitchell JB Baker CS Impact of atrial fibrillation on mortality, stroke and medical costs. Arch Intern Med 1998; 158:229–34. doi:10.1001/archinte.158.3.229

45http://www.statistics.gov.uk/cci/nugget.asp?ID=6

46 Moore D Aveyard P Connock M Effectiveness and safety of nicotine replacement therapy assisted reduction to stop smoking: systematic review and meta-analysis. BMJ 2009; 338:b1024. doi:10.1136/bmj.b1024

47 González EL Johansson S Wallander MA Trends in the prevalence and incidence of diabetes in the UK: 1996–2005. J Epidemiol Community Health 2009; 63:332–6. doi:10.1136/jech.2008.080382

48 Pell JP Haw S Cobbe S Smoke-free legislation and hospitalizations for acute coronary syndrome. N Engl J Med 2008; 359:482–91. doi:10.1056/NEJMsa0706740

49 Cesaroni G Forastiere F Agabiti N Effects of the Italian smoking ban on population rates of acute coronary events. Circulation 2008; 117: 1183–88. doi:10.1161/CIRCULATIONAHA.107.729889

50Department of Health. Putting prevention first – vascular checks: risk assessment and management. London: DOH; 2008. Available from: http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_090278.pdf